Nimotuzumab Combined With Chemoradiotherapy in the Treatment of Unresectable Locally Advanced or Oligometastatic Pancreatic Cancer

Inclusion Criteria: 1. Confirmed by histological or cytological examination as pancreatic adenocarcinoma; 2. Confirmed by imaging as locally advanced or oligometastatic (number of metastatic lesions ≤ 3); 3. Evaluated by the clinical doctor as inoperable or the patient refuses surgery; 4. ECOG PS score 0-1; 5. No radiotherapy has been performed on the upper abdomen before, and no any palliative chemotherapy or other systemic anti-tumor treatment has been received; 6. According to the RECIST 1.1 evaluation criteria, there are measurable lesions; 7. Sufficient organ and bone marrow functions Exclusion Criteria: 1. Previous history of abdominal radiotherapy. 2. Those with a history of other malignant tumors (excluding cured skin basal cell carcinoma and cervical carcinoma in situ). 3. Those allergic to the drugs or their components used in this protocol. 4. Those with known HIV or syphilis infection, or currently in the active stage of hepatitis (hepatitis B or hepatitis C). 5. Those who have undergone major surgery within 30 days before screening. 6. Those who have used EGFR monoclonal antibody or EGFR-TKI within 30 days before screening. 7. Pregnant or lactating women. 8. Those judged by the investigator to have other reasons unsuitable for participating in this study.